A carregar...
A paradigm shift in biomarker guided oncology drug development
Over the past couple of decades, biomarker driven enrichment clinical trials have proven to be an important tool in clinical drug development, especially for targeted anti-cancer drugs. By the end of 2018, more than 30 drugs have been developed in conjunction with a biomarker test and have a regulat...
Na minha lista:
| Publicado no: | Ann Transl Med |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6511563/ https://ncbi.nlm.nih.gov/pubmed/31157269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.03.36 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|